Aethlon Medical AI Stock Analysis
Want to see AEMD full AI Analyst Report?
Aethlon Medical (AEMD) AI Stock Analysis
Aethlon Medical
(NASDAQ:AEMD)
The score is primarily held down by very weak financial performance—minimal/zero recent revenue, persistent losses, and ongoing cash burn indicating high funding dependence. Technicals provide only moderate support with improving short-term momentum but a still-weak longer-term trend. Earnings-call progress in the clinical program and cost discipline helps offset some risk, but the data remains preliminary and future funding needs remain a major overhang.
Aethlon Medical (AEMD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.79M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.55M
- Price to Earnings (P/E)
- -0.5
- Beta (1Y)
- 0.74
- Revenue Growth
- ―
- EPS Growth
- 90.69%
- Country
- US
- Employees
- 9
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Aethlon Medical Business Overview & Revenue Model
Company Description
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon...
Aethlon Medical Earnings Call Summary
The call balanced tangible near-term progress with clear caveats. Positives include advancement into the final clinical cohort, encouraging Cohort 2 biomarker signals, a peer-reviewed Long COVID preclinical publication, ongoing R&D expansion, an improved post-quarter cash position following a ~$4.0M financing, and an 11.9% reduction in operating expenses. Key negatives are that clinical observations are preliminary and based on very small sample sizes, statistical analyses are pending, dosing is logistically constrained, and larger trials will require additional capital or partnerships. Overall, the company shows disciplined resource management and meaningful early scientific signals but faces validation, scale and funding headwinds before efficacy or regulatory clarity can be established.
Q1-2027 Updates
Positive Updates
Negative Updates
Company Guidance
The company provided specific operational and clinical guidance: for the fiscal Q1 ended June 30, 2026 it reported approximately $4.9M in cash (and subsequently raised ~ $4M in gross proceeds), believes cash is sufficient to fund operations for at least the next 12 months, and cut consolidated operating expenses 11.9% to about $1.6M (from $1.8M a year earlier); clinically, Aethlon is in the final (third) cohort of its Australian oncology trial (needs 2 more participants to complete treatment if no device-related SAEs or dose‑limiting toxicities occur), Cohort 3’s first patient received three 4‑hour Hemopurifier treatments over one week and is 8 weeks into follow‑up with no device‑related SAEs/DTLs, Cohort 2 (three participants) received two 4‑hour treatments and Cohort 1 received one 4‑hour treatment, central lab measurements of EVs, microRNAs and lymphocyte subsets for Cohort 2 are complete and showed decreases in total and tumor‑derived EVs, reductions in microRNAs linked to cancer progression, and increases in lymphocyte subsets with directional biomarker changes that persisted to 8 weeks (vs ~2–3 weeks in Cohort 1); next steps are data analysis, a clinical study report, preregistration discussions with regulators, and a goal to complete all Hemopurifier treatments and the 8‑week follow‑up period by end of calendar 2026 (or early 2027).
Aethlon Medical Financial Statement Overview
Summary
Financials are extremely weak: revenue has effectively fallen to zero, operating losses remain large and persistent, and cash flow is consistently negative with very high TTM cash burn cited. Low reported leverage is a relative positive, but it is outweighed by ongoing losses, negative returns on equity, and elevated funding dependence.
Income Statement
7Very NegativeBalance Sheet
48NeutralCash Flow
6Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 574.25K | 294.17K |
| Gross Profit | -391.71K | 0 | 0 | 0 | 574.25K | 294.17K |
| EBITDA | -7.72M | -6.81M | -13.04M | -11.85M | -11.79M | -10.30M |
| Net Income | -8.07M | -7.15M | -13.39M | -12.21M | -12.03M | -10.42M |
Balance Sheet | ||||||
| Total Assets | 7.33M | 6.33M | 7.36M | 8.25M | 17.51M | 19.42M |
| Cash, Cash Equivalents and Short-Term Investments | 6.49M | 5.03M | 5.50M | 5.44M | 14.53M | 17.07M |
| Total Debt | 172.12K | 336.72K | 649.75K | 940.32K | 1.21M | 729.41K |
| Total Liabilities | 1.28M | 1.45M | 2.24M | 2.48M | 2.44M | 2.43M |
| Stockholders Equity | 6.05M | 4.89M | 5.12M | 5.77M | 15.06M | 17.13M |
Cash Flow | ||||||
| Free Cash Flow | -7.27M | -7.00M | -7.65M | -10.38M | -11.45M | -10.12M |
| Operating Cash Flow | -7.26M | -7.00M | -7.65M | -10.13M | -10.51M | -9.77M |
| Investing Cash Flow | -13.37K | -3,704 | 0 | -250.87K | -943.11K | -349.19K |
| Financing Cash Flow | 7.90M | 6.52M | 7.73M | 1.29M | 8.91M | 17.37M |
Aethlon Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEMD, the sentiment is Negative. The current price of 5.29 is below the 20-day moving average (MA) of 5.38, above the 50-day MA of 5.13, and below the 200-day MA of 7.34, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 48.02 is Neutral, neither overbought nor oversold. The STOCH value of 34.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AEMD.
Aethlon Medical Risk Analysis
Aethlon Medical disclosed 73 risk factors in its most recent earnings report. Aethlon Medical reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksAethlon Medical Peers Comparison
Overall Rating
PEN67Neutral
CERS56Neutral
OM51Neutral
CTSO47Neutral
NUWE47Neutral- AEMD46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| PEN | 67Neutral | $12.65B | 80.43 | 10.44% | ― | 16.98% | -5.62% |
| CERS | 56Neutral | $400.88M | -51.16 | -10.54% | ― | 13.74% | 56.08% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| OM | 51Neutral | $70.32M | -0.96 | -68.03% | ― | 1.58% | 70.22% |
| CTSO | 47Neutral | $15.35M | -0.91 | -1339.98% | ― | 9.04% | -43.07% |
| NUWE | 47Neutral | $2.65M | -0.00 | -408.34% | ― | 10.28% | 95.85% |
| AEMD | 46Neutral | $8.49M | -0.50 | -141.22% | ― | ― | 90.69% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AEMD | Aethlon | 5.29 | -14.96 | -73.88% | |
| CERS | Cerus Corporation | 1.99 | 0.46 | 29.74% | |
| NUWE | Nuwellis, Inc. | 4.90 | -767.48 | -99.37% | |
| CTSO | Cytosorbents Corp | 4.87 | -8.25 | -62.89% | |
| PEN | Penumbra Inc. | 320.91 | 42.40 | 15.22% | |
| OM | Outset Medical, Inc. | 3.73 | -1.19 | -24.19% |
Aethlon Medical Corporate Events
Aethlon Medical Reports Second-Quarter Results and Corporate Update
NegativeOn November 12, 2026, Aethlon Medical reported fiscal second-quarter results for the quarter ended September 30, 2026, and a corporate update. The company said it entered a merger agreement with North Immunology on September 17, 2026, implemented wor...
Aethlon Medical Expands Authorized Common Stock Capacity
PositiveAt the 2026 Annual Meeting of Stockholders held on October 1, 2026, Aethlon Medical, Inc. shareholders approved an amendment to the company’s Articles of Incorporation to significantly expand its authorized common stock from 20,000,000 to 200,000,000...
Aethlon Medical Shareholders Expand Capital Structure Flexibility
PositiveOn October 1, 2026, Aethlon Medical held its annual shareholder meeting virtually, with approximately 56.21% of its 711,136 outstanding common shares represented, establishing a quorum for voting on corporate governance and financing matters. Shareho...
Aethlon Medical Announces Merger with North Immunology
PositiveAethlon Medical, Inc., headquartered in San Diego, is a medical therapeutic company developing the Hemopurifier, a clinical-stage immunotherapeutic device aimed at removing cancer-promoting exosomes and life-threatening viruses from the bloodstream,...
Aethlon Medical Updates Executive Severance Terms After Change
NeutralOn September 11, 2026, Aethlon Medical, Inc. amended the employment agreements of Chief Executive Officer and Chief Financial Officer James B. Frakes and Chief Medical Officer Steven P. LaRosa, M.D., to modify how severance and health care continuati...
Aethlon Medical Completes Warrant Exercises, Clarifying Capitalization
PositiveAethlon Medical, Inc. reported that, following recent exercises of certain pre-funded warrants, it had 1,604,095 shares of common stock outstanding as of the close of business on August 28, 2026. With all previously outstanding pre-funded warrants no...
Aethlon Medical Advances Hemopurifier Trials and Bolsters Liquidity
PositiveOn August 13, 2026, Aethlon Medical reported results for its fiscal first quarter ended June 30, 2026, highlighting progress in its Hemopurifier program, including dosing the first participant in the third and final cohort of its Phase 1 oncology stu...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026